logo
Share SHARE
FONT-SIZE Plus   Neg

Forest Labs., Gedeon Report Results From 2 Phase III Trials Of Cariprazine

Forest Laboratories, Inc. (FRX) and Gedeon Richter Plc announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for treating acute exacerbation of schizophrenia.

For the primary endpoint in each study, the Positive And Negative Syndrome Scale, the data showed that cariprazine-treated patients experienced significant symptom improvement compared to placebo-treated patients.

Besides, all doses showed statistically significant separation from placebo starting at week 2 and at each subsequent time point with the higher dose showing separation as early as week 1 of treatment. Further analyses of the data in each study will be completed in the coming weeks.

Forest Labs noted that the results of these 2 studies were consistent with the results of the previously completed placebo-controlled Phase IIb fixed-dose study in this population.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
McDonald's offers smartphone lockers so as to help customers spend quality time during family meals. The "Phone off. Fun On" campaign, introduced recently in a Singapore branch, aims to encourage diners to take a break from the virtual world to have real conversations over meals. U.S. Bancorp (USB) reported net income of $1.56 billion for the third quarter of 2017, or $0.88 per share, compared to $1.50 billion, or $0.84 per share, in the third quarter of 2016. On average, 28 analysts polled by Thomson Reuters expected the company to report profit per share of $0.88 for the quarter.... Dutch semiconductor equipment maker ASML Holding NV reported Wednesday higher profit in its third quarter as sales were boosted mainly with strong demand for DUV Systems. Meanwhile, margin declined. Looking ahead, the company projects sequentially lower sales in its fourth quarter. For fiscal 2017, the company maintained forecast for higher sales.
comments powered by Disqus
Follow RTT